Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
HUMA
$1.12
$
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Beta
1.917
Average Volume
Market Cap
Last Dividend
CIK
0001818382
ISIN
US44486Q1031
CUSIP
44486Q103
CEO
Laura E. Niklason
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
218
IPO Date
2020-12-01
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting | - Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - - Long-term durability results showed no dilatation nor narrowing of Symvess diameter out to 36 months - DURHAM, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of long-term data assessing the durability of Symvess in extremity arterial trauma patients at the Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society (VESS) in Olympic Valley, CA. | GlobeNewsWire | 2026-02-18 08:00:00 |
| Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know | Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close. | Zacks Investment Research | 2026-02-10 19:00:38 |
| Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels | DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries. | GlobeNewsWire | 2026-02-09 08:00:00 |
| Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider | In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.02, indicating a +2.24% shift from the previous trading day. | Zacks Investment Research | 2026-02-02 19:01:33 |
| Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications | - Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte's Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage – DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the results of a five-year retrospective analysis of hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury. | GlobeNewsWire | 2026-01-08 08:00:00 |
| Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? | Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year. | Zacks Investment Research | 2026-01-07 10:41:19 |
| Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel | - Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV™ or Symvess) for arterial trauma repair during the first quarter of 2026. | GlobeNewsWire | 2026-01-05 08:00:00 |
| Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair | - Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in the Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT). | GlobeNewsWire | 2025-12-22 08:00:00 |
| Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital | DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P. | GlobeNewsWire | 2025-12-16 08:00:00 |
| Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest? | When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? | Zacks Investment Research | 2025-12-05 10:31:32 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13D/A | 2026-01-09 | 2026-01-09 | View Filing |
| 8-K | 2025-12-16 | 2025-12-16 | View Filing |
| 424B5 | 2025-12-16 | 2025-12-16 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| 424B3 | 2025-12-15 | 2025-12-15 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 8-K | 2025-11-26 | 2025-11-26 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13D/A | 2025-10-16 | 2025-10-16 | View Filing |
| 8-K | 2025-10-07 | 2025-10-07 | View Filing |
| 424B3 | 2025-10-07 | 2025-10-07 | View Filing |
| EFFECT | 2025-09-23 | 2025-09-23 | View Filing |
| 424B3 | 2025-09-22 | 2025-09-22 | View Filing |
| 8-K | 2025-09-18 | 2025-09-17 | View Filing |
| S-3 | 2025-09-12 | 2025-09-12 | View Filing |
| 4 | 2025-08-20 | 2025-08-20 | View Filing |
| 4 | 2025-08-20 | 2025-08-20 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| SC 13D/A | 2025-05-22 | 2025-05-22 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-18 | 2025-04-17 | View Filing |
| PRE 14A | 2025-04-17 | 2025-04-17 | View Filing |
| 4 | 2025-04-15 | 2025-04-15 | View Filing |
| 4 | 2025-04-14 | 2025-04-14 | View Filing |
| 4 | 2025-04-14 | 2025-04-14 | View Filing |
| 4 | 2025-04-08 | 2025-04-08 | View Filing |
| 4 | 2025-04-08 | 2025-04-08 | View Filing |
| 4 | 2025-04-08 | 2025-04-08 | View Filing |
| S-8 | 2025-03-31 | 2025-03-31 | View Filing |
| 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| 424B5 | 2025-03-26 | 2025-03-26 | View Filing |
| 424B3 | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2024-12-20 | 2024-12-20 | View Filing |
| 4 | 2024-12-20 | 2024-12-20 | View Filing |
| 4 | 2024-12-20 | 2024-12-20 | View Filing |
| 4 | 2024-12-20 | 2024-12-20 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| 4 | 2024-12-04 | 2024-12-04 | View Filing |
| 4 | 2024-11-21 | 2024-11-21 | View Filing |
| 4 | 2024-11-21 | 2024-11-21 | View Filing |
| SC 13D/A | 2024-11-20 | 2024-11-20 | View Filing |
| 4 | 2024-11-20 | 2024-11-20 | View Filing |
| 4 | 2024-11-20 | 2024-11-20 | View Filing |
| SC 13D/A | 2024-11-18 | 2024-11-18 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 424B3 | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-10-28 | 2024-10-28 | View Filing |
| SC 13G | 2024-10-24 | 2024-10-24 | View Filing |
| 8-K | 2024-10-07 | 2024-10-07 | View Filing |
| 424B3 | 2024-10-04 | 2024-10-04 | View Filing |
| 424B3 | 2024-09-25 | 2024-09-25 | View Filing |
| 8-K | 2024-09-25 | 2024-09-24 | View Filing |
| 4 | 2024-09-16 | 2024-09-16 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| 4 | 2024-09-03 | 2024-09-03 | View Filing |
| 4 | 2024-09-03 | 2024-09-03 | View Filing |
| SC 13D/A | 2024-09-03 | 2024-09-03 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-15 | 2024-08-15 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Macd Rsi Composite Strategy | 35.78% | 1 | 1 | 2.31 | 0 | 42.07 |
| Larry Williams PercentR Strategy | 35.78% | 1 | 13 | 0.79 | 0 | 42.07 |
| Keltner Channel Strategy | 35.78% | 1 | 19 | 0.66 | 0 | 42.07 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | x | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |